Adjuvant colon cancer chemotherapy: where we are and where we'll go

SUMMARY Many patients with early-stage colon cancer are cured with surgery alone, even if the standard of care remains an uniform approach to adjuvant chemotherapy based primarily on tumour stage. Consequently, it is important to individualize decision-making in this subset of patients with the aim...

Full description

Saved in:
Bibliographic Details
Published in:Cancer treatment reviews 2010-11, Vol.36, p.S34-S41
Main Authors: Lombardi, L, Morelli, F, Cinieri, S, Santini, D, Silvestris, N, Fazio, N, Orlando, L, Tonini, G, Colucci, G, Maiello, E
Format: Article
Language:English
Subjects:
Adjuvant chemotherapy
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Biomarkers, Tumor - analysis
Chemotherapy, Adjuvant
Colon cancer
Colonic Neoplasms - diagnosis
Colonic Neoplasms - drug therapy
Colonic Neoplasms - genetics
Colonic Neoplasms - mortality
Colonic Neoplasms - pathology
Colonic Neoplasms - surgery
Fluorouracil - administration & dosage
Hematology, Oncology and Palliative Medicine
Humans
Levamisole - administration & dosage
Loss of Heterozygosity
Lymphatic Metastasis
Microsatellite Instability
Molecular markers
Neoplasm Staging
Predictive Value of Tests
Prognosis
Survival Rate
Trial
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:SUMMARY Many patients with early-stage colon cancer are cured with surgery alone, even if the standard of care remains an uniform approach to adjuvant chemotherapy based primarily on tumour stage. Consequently, it is important to individualize decision-making in this subset of patients with the aim to identify potential prognostic and predictive markers in colon cancer. While 5-fluorouracil, leucovorin, and oxaliplatin are widely known as gold treatment in the post-operative of stage III, well-validated molecular markers might help define which patients with stage II disease are likely to benefit from adjuvant therapy as well. Herein we review the use of adjuvant chemotherapy in colon cancer and analyzed the date on the clinical development of molecular markers to individualize another therapeutic approach in colon cancer.
ISSN:0305-7372
1532-1967
DOI:10.1016/S0305-7372(10)70018-9